UBS lifts Labcorp price target to $420, keeps Buy
Alpha Vantage · Moomoo · · AI-summarised by FinFlash
UBS raised its price target on Labcorp to $420 from $380 while reiterating a Buy rating, citing a positive outlook on the company's future performance. The new target sits well above the $354.50 analyst average and the $368.16 share price. The move signals continued sell-side confidence in the diagnostics group, a supportive signal for holders of the stock.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.